Trump anuncia corte de preços em medicamentos para perda de peso com Lilly e Nordisk

US reasserts pricing leverage over multinational pharma corporations through executive pressure, potentially establishing precedent for drug price negotiations. Novo Nordisk (Danish) and Eli Lilly (US) capitulate to domestic political pressure, signaling shift toward state-directed pricing. This may embolden other nations to demand similar concessions, fragmenting global pharmaceutical pricing structures and reducing company profit margins internationally.

Similar to Nixon-era price controls on pharmaceuticals (1971-1974) and more recently, Biden's Medicare negotiation provisions (IRA 2022), representing cyclical US government intervention in drug pricing during periods of political focus on healthcare costs.

Consumers gain substantially lower out-of-pocket costs for weight-loss medications (81% reduction for Wegovy), improved accessibility through expanded Medicare/Medicaid coverage, and potential increased demand. However, pharmaceutical companies face margin compression, which may affect R&D investment and drug innovation timelines.

Sets precedent for government price negotiation in pharmaceuticals, potentially triggering similar interventions for other drug categories. May accelerate regulatory pressure on drug pricing globally. Requires implementation of TrumpRX platform and coordination between CMS and private insurers. Could influence international pricing strategies and trade negotiations.